Targeting Dysbiosis: Rebyota as a Novel Strategy for Recurrent CDI Prevention

Clostridioides difficile is a bacterium that colonizes a patient's gastrointestinal tract after the use of systemic antibiotics. This infection, also called CDI, causes severe diarrhea and can be life-threatening. In some patients, CDI recurs, creating a dangerous cycle. Recurrent CDI (rCDI) persists because systemic antibiotics induce dysbiosis, disrupting the gut microbiota’s metabolic functions and compromising the intestinal epithelial barrier. This study was conducted as a literature review evaluating the safety, efficacy, mechanism of action, and clinical use of Rebyota in preventing rCDI. Rebyota is the first FDA-approved (2023) live biotherapeutic designed to restore eubiosis in adult patients after antibiotic treatment. It is a rectally administered suspension made from carefully screened human donor stool and contains a diverse variety of live microorganisms. We have also considered the immunological mechanisms and inflammatory biomarkers involved in CDI severity. CDI is characterized by a pro-inflammatory cytokine response driven by C. difficile exotoxins. Key inflammatory mediators include: IL-1β, IL-6, IL-8, and IL-17A. These markers are significantly upregulated in CDI patients. Although its exact mechanism of action has not been fully established, the microbiota provided by Rebyota may outcompete C. difficile, thus restoring microbial diversity in the gastrointestinal tract. Additionally, this biotherapy promotes the production of bacteriocins, repair of epithelial barrier integrity, and modulation of host immune responses. In particular, the butyrate-producing bacterial species within the formulation can help to alleviate intestinal inflammation and improve barrier integrity given that they are known to downregulate the proinflammatory mediators, such as IL-6 and IL-12, in intestinal macrophages. In conclusion, these studies demonstrate that Rebyota is a highly effective, single-dose intervention for preventing rCDI. While it may cause mild gastrointestinal side effects, it offers a reliable alternative to traditional fecal microbiota transplantation and prolonged antibiotic use. In conclusion, as a recently approved therapy, further investigation is required regarding its long-term immunological, safety, and efficacy outcomes. Furthermore, elucidating the mechanistic pathway underlying rCDI and its biologic therapies could lead to the development of other effective treatments for this disease.